Rhinomed’s Mute is fastest growing nasal strip in US
Rhinomed Ltd (ASX:RNO), a leader in airway technology and the developers of MuteTM, has informed the market that its Mute nasal stent is the fastest growing product in the nasal strip category in US based drug stores.
Rhinomed is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies.
The company is monetising applications of its technology portfolio in the sport, sleep, well-being and drug delivery markets.
The DrugStores News Management's Annual Drugstore State of the Industry report lists Mute as the fastest growing product in the nasal strip category, growing sales at 56.6% in US Dollar terms and 57.2% in units for the 52 week period ended April 21, 2019.
This development comes as the company’s broader operations are also delivering promising growth.
Revenue for the March quarter of more than $1 million represented a 64% increase on the previous corresponding quarter, and the year-to-date income run rate is tracking well ahead of fiscal 2018.
As well as the Mute product line, order volumes for the group’s new ProntoTM rechargeable vapour delivery technology have been encouraging.
New markets poised to deliver robust growth
While the US pharmacy (drug store) market consists of some 67,000 stores, Mute has only recently achieved distribution into 9000 of these stores.
Mute’s rapid growth against exceptionally well established and supported brands such as GlaxoSmithKline’s (LON:GSK) Breathe Right strip product demonstrates Mute’s growing appeal and its potential to achieve further distribution in the US drug store market and then more broadly within the food, mass and specialty retail markets in the US.
As the category leader, Breath Right and Breathe Right Extra achieved sales in excess of US$22 million from pharmacy alone and shipped nearly 2 million units to achieve more than 50% market share.
With only a small store presence and having only begun to make inroads in building brand awareness, the company believes Mute has significant potential to grow and disrupt the sector further.
Highlighting Mute’s premium position and its scope for growth in a niche market, chief executive Michael Johnson said, ‘’Rhinomed is pleased to see that the investment in building the Mute brand is delivering traction.
"Mute is the premium product within the category and is continuing to deliver strong margins for our retail partners.
"As the innovator within the market, Rhinomed will continue to build upon this success to expand our retail presence in the US and global pharmacy market.’’
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.